Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Zacks News
Endo (ENDP) Beats on Q2 Earnings & Sales, Raises Guidance
by Zacks Equity Research
Endo International (ENDP) gains on better-than-expected Q2 results on the back of growth in demand for Xiaflex and momentum in its Sterile Injectables business.
Perrigo (PRGO) Beats on Q2 Earnings, Cuts View, Shares Down
by Zacks Equity Research
Perrigo (PRGO) reports mixed second-quarter 2018 results and lowers revenue and adjusted earnings guidance for 2018.
Sarepta (SRPT) Q2 Loss Narrows, Exondys 51 Drives Sales
by Zacks Equity Research
Sarepta's (SRPT) loss per share is narrower than the Zacks Consensus Estimate while sales also beat the same. Exondys 51 continues its strong performance.
Infinity (INFI) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Infinity (INFI) posts narrower-than-expected loss in the second quarter of 2018 and provides update on pipeline candidate, IPI 549.
Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise
by Zacks Equity Research
Horizon Pharma (HZNP) beat earnings and sales estimates in the second quarter of 2018.
Mallinckrodt (MNK) Beats on Q2 Earnings and Sales, Ups View
by Zacks Equity Research
Mallinckrodt (MNK) surges following earnings and sales beat in the second quarter. Increase in annual guidance is impressive as well.
Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
The FDA accepts Catalyst's (CPRX) NDA for its lead pipeline candidate, Firdapse, for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) and an action date of Nov 28, 2018 is set for the same.
Jazz Pharma's (JAZZ) Stock Down Despite Q2 Earnings Beat
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q2. However, sales of its newest drug, Vyxeos disappoint. Stock down 7% in after-hours trading.
Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges
by Zacks Equity Research
The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.
Arena Pharmaceuticals (ARNA) Q2 Loss Wider Than Expected
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) misses second-quarter earnings estimates. Its three key pipeline candidates, ralinepag, etrasimod and Olorinab/APD371, remain in focus.
Ironwood (IRWD) Q2 Earnings & Revenues Miss, Shares Down
by Zacks Equity Research
Ironwood Pharmaceuticals (IRWD) misses estimates on both counts in the second quarter. The company will be separated into two entities for better management.
Medicines Company (MDCO) Q2 Loss Narrows, Revenues Tank Y/Y
by Zacks Equity Research
The Medicines Company (MDCO) beats earnings estimates while missing the same for revenues in the second quarter.
Ophthotech (OPHT) Q2 Loss Narrows, Zimura Progress On Track
by Zacks Equity Research
Ophthotech reports narrower-than-expected loss in the second quarter.
Geron (GERN) Q2 Loss In Line, Revenues Up Y/Y, Shares Down
by Zacks Equity Research
Geron (GERN) meets earnings estimates on higher sales in the second quarter. Operating expenses however increase year over year.
Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit
by Zacks Equity Research
Impressive second-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.
Vertex (VRTX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) Q2 rides high on earnings and revenue beat.
Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK
by Zacks Equity Research
The going has been good for the pharma giants, which reported second-quarter results so far. Let us see what is in store for biotech bigwig GILD, VRTX and large-cap pharma company GSK.
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
Vertex Pharma (VRTX) is expected to beat estimates when it reports second-quarter earnings on Jul 25.
Company News For Jul 2, 2018
by Zacks Equity Research
Companies in the news are: STZ,KBH,VRTX,FCAU
Vertex's Shares Rally as a Rival's CF Candidate Disappoints
by Zacks Equity Research
Vertex Pharmaceuticals' (VRTX) stock rallies on disappointing study results on rival Galapagos' cystic fibrosis candidate. Vertex's third CF drug receives approval in Canada.
4 Drug and Biotech Stocks Awaiting FDA Decisions in July
by Kinjel Shah
In the first six months of the year, the FDA grants approval to 17 new treatments.
Sarepta Pharma Pushes Two Biotech ETFs to New Highs
by Sweta Killa
The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.
Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO
by Zacks Equity Research
The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.
Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex
by Zacks Equity Research
Zacks Investment Ideas feature highlights: CRISPR, Intellia Therapeutics, Editas and Vertex
Vertex/CRISPR's Sickle Disease Candidate Put on Hold by FDA
by Zacks Equity Research
FDA places clinical hold on a Vertex (VRTX) and CRISPR Therapeutics' IND application for CTX001 for the treatment of sickle cell disease.